MX2011009147A - Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh. - Google Patents

Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh.

Info

Publication number
MX2011009147A
MX2011009147A MX2011009147A MX2011009147A MX2011009147A MX 2011009147 A MX2011009147 A MX 2011009147A MX 2011009147 A MX2011009147 A MX 2011009147A MX 2011009147 A MX2011009147 A MX 2011009147A MX 2011009147 A MX2011009147 A MX 2011009147A
Authority
MX
Mexico
Prior art keywords
tromethamine
addition salts
acid derivatives
azabiphenylaminobenzoic acid
dhodh inhibitors
Prior art date
Application number
MX2011009147A
Other languages
English (en)
Inventor
Xavier Serra Masia
Nuria Garcia Gonzalez
Francesc Carrera Carrera
Montserrat Julia Jane
Laurent Debethune
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011009147(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2011009147A publication Critical patent/MX2011009147A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a nuevas sales de adición cristalinas de (i) trometamina con (ii) un derivado de ácido azabifenilaminobenzoico de fórmula (I) (ver fórmula (I)) en la que R1 se selecciona del grupo que consiste en alquilo C1-C4, cicloalquilo C3-C4 y CF3, G1 se selecciona de átomos de nitrógeno y grupos CH, C(CH3) y C(CF3), y G2 representa un grupo fenilo opcionalmente sustituido con uno o dos sustituyentes seleccionados de cloro, fluoro, metoxi, etoxi, isopropoxi, trifluorometoxi, CF3, y CONR7R8, en donde R7 es hidrógeno y R8 es ciclopropilo o R7 y R8 junto con el átomo de nitrógeno al que están unidos forman un grupo de fórmula (ver fórmula) donde n es 1; y sus solvatos farmacéuticamente aceptables.
MX2011009147A 2009-03-13 2010-03-11 Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh. MX2011009147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382032A EP2230232A1 (en) 2009-03-13 2009-03-13 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
PCT/EP2010/001549 WO2010102825A1 (en) 2009-03-13 2010-03-11 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors

Publications (1)

Publication Number Publication Date
MX2011009147A true MX2011009147A (es) 2011-09-15

Family

ID=40671396

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009147A MX2011009147A (es) 2009-03-13 2010-03-11 Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh.

Country Status (21)

Country Link
US (1) US20120003183A1 (es)
EP (2) EP2230232A1 (es)
JP (1) JP2012520251A (es)
KR (1) KR20110126695A (es)
CN (1) CN102341372A (es)
AR (1) AR075737A1 (es)
AU (1) AU2010223527A1 (es)
CA (1) CA2754785A1 (es)
CL (1) CL2011002213A1 (es)
CO (1) CO6501157A2 (es)
EA (1) EA201101298A1 (es)
EC (1) ECSP11011384A (es)
IL (1) IL214517A0 (es)
MX (1) MX2011009147A (es)
NZ (1) NZ594491A (es)
PE (1) PE20120328A1 (es)
SG (2) SG10201400568PA (es)
TW (1) TW201033177A (es)
UY (1) UY32465A (es)
WO (1) WO2010102825A1 (es)
ZA (1) ZA201105743B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
CN110903219A (zh) * 2018-09-18 2020-03-24 广东东阳光药业有限公司 酰胺衍生物的盐及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
EP1935416A3 (en) 2001-04-05 2008-10-22 Aventis Pharma Inc (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis
PE20030120A1 (es) * 2001-06-19 2003-02-12 Merck & Co Inc Sal amina de un antagonista de receptor de integrin
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581478A1 (en) 2002-12-23 2005-10-05 4Sc Ag Dhodh-inhibitors and method for their identification
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
CN1993125A (zh) 2004-05-21 2007-07-04 Uab研究基金会 涉及嘧啶合成抑制剂的组合物和方法
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
CN101043883A (zh) 2004-10-19 2007-09-26 安万特药物公司 (z)-2-氰基-3-羟基-丁-2-烯酸-(4'-三氟甲基苯基)-酰胺用于治疗炎症性肠病的用途
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico

Also Published As

Publication number Publication date
NZ594491A (en) 2013-11-29
UY32465A (es) 2010-05-31
SG173824A1 (en) 2011-09-29
AU2010223527A1 (en) 2011-08-25
TW201033177A (en) 2010-09-16
ECSP11011384A (es) 2011-11-30
CL2011002213A1 (es) 2012-03-09
EA201101298A1 (ru) 2012-04-30
ZA201105743B (en) 2012-04-25
CA2754785A1 (en) 2010-09-16
JP2012520251A (ja) 2012-09-06
EP2406222A1 (en) 2012-01-18
CO6501157A2 (es) 2012-08-15
KR20110126695A (ko) 2011-11-23
AR075737A1 (es) 2011-04-20
US20120003183A1 (en) 2012-01-05
IL214517A0 (en) 2011-09-27
EP2230232A1 (en) 2010-09-22
PE20120328A1 (es) 2012-03-29
CN102341372A (zh) 2012-02-01
WO2010102825A1 (en) 2010-09-16
SG10201400568PA (en) 2014-07-30

Similar Documents

Publication Publication Date Title
CO6261379A2 (es) Compuestos de ciclopentandiona y derivados utiles como herbicidas
EA201591000A1 (ru) Пирролобензодиазепины
MX2011009147A (es) Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh.
ECSP12012212A (es) Derivados de ariletinilo
MX2011007455A (es) Derivados oxadiazol como agonistas de los receptores de esfingosina-1-fosfato 1 (s1p1).
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
RS52166B (en) AMINO-HETEROCYCLIC COMPOUNDS
WO2012003405A4 (en) Sgc stimulators
PH12016502037A1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
RS54175B1 (en) BROMODOMEN INHIBITORS AND THEIR APPLICATION
MX2010007833A (es) Compuestos que tienen actividad antagonista de crth2.
RS53451B (en) INHIBITORI P70 S6 KINAZE
MX2012001313A (es) Compuesto espirociclicos que contienen nitrogeno y su uso medicinal.
EA201170096A1 (ru) Замещенные производные пиримидона
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
MX2011009146A (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh.
MY169179A (en) Novel piperidine compound or salt thereof
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
MX360667B (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
MY159870A (en) Piperazine compound capable of inhibiting prostaglandin d synthase
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MX2011009746A (es) Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-abril-metil]-hetero benzamida, su prepracion y su uso en terapeutica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal